It
is interesting what one finds when one follows the research trail. The results
of my search showed that Czeizel’s research has been focused mainly Folic
acid for preventing neural tube defects. He has written lots of papers on folic
acid in preconceptual multivitamins. I read 10 abstracts before I could be reasonably
sure, but it appears that all the articles are about the same cohort of women.
The only reference to Sifakis etc is (2). in the mumsweb site and Taylor
Nelson etc seem to be a research site, but no hint of it being a medical
research lab. So it appears that elevit has been formulated from the
recommendations of one trial of about 5,000 women in Hungary. MM
“ELEVIT should
be taken three months prior to conception and continued throughout pregnancy
and breastfeeding. However, you can start taking ELEVIT at any time during your
pregnancy. ELEVIT is Australia’s
No. 1 pregnancy supplement, and is only available at your local pharmacy. Mandatories: The Australian formulation of Elevit is the same as that
used in the Czeizel study except that it does not contain Vitamin A. Always read the label. Use on as directed. See the label
for full list of ingredients. Elevit is a registered trademark of Roche Products Pty. Ltd.
1. Czeizel AE. BMJ 1993;306:1645-1648. 2. Sifakis S. and Pharmakides G. Ann NY Aced Scien.
2000;900:125-136. 3. Taylor Nelson
Sofres Research, 2002”.
.
About Taylor Nelson Sofres Taylor
Nelson Sofres is an international leader in media research and TV audience measurement. The research group has been ...
|
Prevention
of congenital abnormalities by periconceptional multivitamin supplementation.
Czeizel AE.
Department of Human Genetics and Teratology, National Institute of
Hygiene-WHO Collaborating Centre for the Community Control of Hereditary
Diseases, Budapest, Hungary.
OBJECTIVE--To study the effect of periconceptional multivitamin
supplementation on neural tube defects and other congenital abnormality
entities. DESIGN--Randomised controlled trial of supplementation with
multivitamins and trace elements. SETTING--Hungarian family planning
programme. SUBJECTS--4156 pregnancies with known outcome and 3713 infants
evaluated in the eighth month of life. INTERVENTIONS--A single tablet of a
multivitamin including 0.8 mg of folic acid or trace elements supplement
daily for at least one month before conception and at least two months after
conception. MAIN OUTCOME MEASURES--Number of major and mild congenital
abnormalities. RESULTS--The rate of all major congenital abnormalities was
significantly lower in the group given vitamins than in the group given trace
elements and this difference cannot be explained totally by the significant
reduction of neural tube defects. The rate of major congenital abnormalities
other than neural tube defects and genetic syndromes was 9.0/1000 in
pregnancies with known outcome in the vitamin group and 16.6/1000 in the
trace element group; relative risk 1.85 (95% confidence interval 1.02 to
3.38); difference, 7.6/1000. The rate of all major congenital abnormalities
other than neural tube defects and genetic syndromes diagnosed up to the
eighth month of life was 14.7/1000 informative pregnancies in the vitamin
group and 28.3/1000 in the trace element group; relative risk 1.95 (1.23 to
3.09); difference, 13.6/1000. The rate of some congenital abnormalities was
lower in the vitamin group than in the trace element group but the
differences for each group of abnormalities were not significant.
CONCLUSIONS--Periconceptional multivitamin supplementation can reduce not
only the rate of neural tube defects but also the rate of other major
non-genetic syndromatic congenital abnormalities. Further studies are needed
to differentiate the chance effect and vitamin dependent effect.
Publication Types:
·
Clinical
Trial
·
Randomized
Controlled Trial
PMID: 8324432 [PubMed - indexed for MEDLINE]
|
|
|
|
|
|
|
|
|
|
|
|
- [ozmidwifery] ELEVIT RESEARCH Mary Murphy
-
